Quest Diagnostics ( (DGX) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Quest Diagnostics shares came under pressure even as Truist lifted its price target, with the broker’s decision to stick with a Hold rating signaling limited near-term upside. The move suggests that, despite refreshed long‑term estimates out to 2028, analysts see the stock as fairly valued rather than poised for a strong rally.
For longer-term investors, Quest’s steady growth in testing volumes and its push into more advanced, specialized diagnostics point to a business that can keep expanding as healthcare demand rises. However, pressure on profit margins and uncertainty around insurance and government reimbursement mean future earnings could be squeezed, leaving less room for big cash returns to shareholders if conditions worsen.
More about Quest Diagnostics
YTD Price Performance: 43.88%
Average Trading Volume: 977,150
Technical Sentiment Signal: Buy
Current Market Cap: $27.2B
For further insights into DGX stock on
TipRanks’ Stock Analysis page.
See more of today’s
top stock gainers and losers.